The demand for clean water is rapidly growing, which has prompted further development of nanomaterials for environmental purification and biomedical research. Photocatalysis is a highly promising oxidation method for the removal of organic and biological pollutants. It is quite evident that there is a serious and pressing demand to design economic treatment techniques, which are cheap and energy independent. In this study, we described the fabrication of Z-scheme heterostructure Er doped ZrO2/Bi2WO6 that effectively enhances visible-light-driven charge separation and redox ability, leading to superior photocatalytic degradation and antibacterial performance. The dual-functionality and high mineralization efficiency demonstrated in this study highlight the potential of the developed photocatalyst for sustainable wastewater treatment and biomedical-related environmental applications. The composite and its constituents were synthesized by hydrothermal approach and characterized in terms of their structural, optical, functional, morphological, photocatalytic and antibacterial properties. The optimized Er-doped ZrO2/Bi2WO6 nanocomposite exhibited excellent photocatalytic performance, achieving 97.02% degradation of the moxifloxacin (MOX) drug under visible light and showed good antibacterial capability against four bacterial strains the order of Escherichia coli > Bacillus fortis > Staphylococcus aureus > Streptococcus canis. Reactive-species scavenging analysis proved that the role of superoxide radicals (•O2−) and hydroxyl (•OH) plays a significant role in the photocatalytic degradation of MOX. The current study highlights the enhanced photocatalytic and antibacterial activity of the Z-scheme Er doped ZrO2/Bi2WO6 heterostructure due to their design and engineering, with applications in multifunctional industries, particularly environmental cleaning and biomedical research.
Stroke is the second leading cause of mortality worldwide, resulting from an interruption of blood flow to the brain, which subsequently diminishes oxygen supply. Although strokes can occur at any age, incidence rises significantly after 55. Vascular dementia, a progressive condition associated with cerebral infarction, is a long-term sequela of stroke that predominantly affects older populations. To date, there is no cure for this form of dementia. Recent experimental studies in rodent models, however, demonstrate promising outcomes in combating neuronal degeneration through gene treatments utilizing brain-derived neurotrophic factor, fibroblast growth factor-2, and vascular endothelial growth factor. These advancements suggest a potential breakthrough in vascular dementia treatment. This comprehensive review delves into the complexities of strokes, exploring their challenges and constraints. Furthermore, we explore the growing field of gene therapy, highlighting successful interventions that may revolutionize the landscape of vascular dementia treatment. This review aims to provide a refined understanding of stroke-related issues and the transformative potential of gene-based interventions in mitigating the burden of vascular dementia.
Obsessive compulsive disorder (OCD) is a challenging mental health condition marked by intrusive thoughts and repetitive actions intended to reduce anxiety or prevent potential harm. Dementia encompasses a range of degenerative brain conditions distinguished by diminished cognitive abilities, memory impairment and challenges in everyday activities. Clinical data suggests a probable association between OCD and dementia, with individuals exhibiting obsessive-compulsive symptoms showing higher risk of developing dementia, like Alzheimer ' s disease. However, the underlying mechanisms linking the two conditions are largely unknown. This in silico network analysis is aimed at understanding the common molecular determinants underlying the pathophysiology of OCD and dementia. For this purpose, genome-wide association study (GWAS) databases were used to identify the genes involved in the pathogeneses of both conditions. Subsequent network analyses of the common genes found to be altered in OCD and dementia was performed to identify potential shared biological pathways and their pathophysiological implications. Our findings indicated significant pathway enrichment and common dysregulated gene modules in both diseases, indicating potential convergence spots for targeted therapeutic approaches. In particular, T-type voltage-sensitive calcium channels, kainate receptors and cAMP signalling regulators were recognized as key mediators linking the pathophysiology of OCD and dementia. Although further experimental data is warranted, our gene set enrichment analysis results may aid in understanding the pathophysiology of these disorders, particularly in cases where they coexist. Further, hub genes linking the two conditions constitute hypothesis-generating leads and promising targets for experimental validation aimed at tackling the intricately interlinked aetiology of dementia and OCD.
The most common autoimmune illness in both developed and under developed countries is rheumatoid arthritis (RA). In the past, RA could not be effectively treated with any existing strategies. However, new medications and therapeutic approaches have been created to combat this condition in the present day as a result of advancements in drug delivery science. Numerous advancements have been made in the therapy formulations for RA that are currently on the market in the last few years. One well-known medication for the treatment of RA is methotrexate (MTX). However, most current treatment formulations have several adverse effects and are unable to completely alleviate all RA symptoms. Combination therapy for the treatment of RA may be more successful than MTX therapy alone in addressing such problems. We discovered that MTX plus infliximab (INF), golimumab (GOL), leflunomide (LEF), folic acid (FA), and azathioprine was more successful than MTX alone because it had less adverse effects and a lower risk of RA relapses. MTX monotherapy has been shown to be less effective than combinations with one or more drugs. We examined the many injectable treatments for RA, focusing on thermo-responsive targeted drug delivery systems as cutting-edge means of delivering MTX, either alone or in conjunction with other treatments. Thermo-responsive in situ hydrogel-based injectables in latest drug delivery systems have the potential to address many of the challenges related to RA treatment and therapy.
Transition-metal (TM)-doped MXenes stand out as highly promising earth-abundant electrocatalysts for the hydrogen evolution reaction (HER), paving the way for cost-effective and sustainable green hydrogen generation. This review surveys the latest developments in TM-doped MXene systems for HER, emphasizing how diverse fabrication routes, including in situ incorporation during MAX-phase synthesis and post-etching modifications via atomic layer deposition (ALD), plasma-enhanced chemical vapor deposition (PECVD), and electrochemical deposition, shape their electronic properties and catalytic efficiency. Insights from d-band center theory, operando spectroscopic techniques, and deliberate active-site tuning are integrated to illustrate pathways toward optimal hydrogen binding energetics (ΔGH* ≈ 0 eV). Benchmark comparisons reveal that carefully engineered TM-doped MXenes frequently deliver overpotentials, Tafel slopes, mass activities, and other metrics that approach or outperform conventional noble-metal catalysts. The review also critically evaluates ongoing limitations, such as susceptibility to oxidation, dopant instability, and nanosheet restacking, while exploring architectural innovations and protective modifications as effective countermeasures. Looking ahead, the discussion highlights transformative opportunities in machine-learning-guided discovery, exploitation of quantum phenomena, and nature-inspired fabrication routes to bridge the gap toward practical, large-scale implementation.
